Global Anti-tumor Drug Market 2020 by Company, Regions, Type and Application, Forecast to 2025
Summary
Market Overview
The global Anti-tumor Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Anti-tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Anti-tumor Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Anti-tumor Drug market has been segmented into Cytotoxic Drugs, Non-cytotoxic Drugs, etc.
By Application, Anti-tumor Drug has been segmented into Alkylating Agents, Anti-metabolism Drugs, Platinum Antineoplastic Agents, Anthracycline antitumor drugs, Microtubule Stabilizer, Endocrine Therapy Drugs, Immunotherapy Drugs, Gene Therapy Drugs, Targeted Antineoplastic Drugs, etc.
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Anti-tumor Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Anti-tumor Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Anti-tumor Drug market.
The report offers in-depth assessment of the growth and other aspects of the Anti-tumor Drug market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Anti-tumor Drug markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.
Competitive Landscape and Anti-tumor Drug Market Share Analysis
Anti-tumor Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Anti-tumor Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Anti-tumor Drug sales, revenue and market share for each player covered in this report.
The major players covered in Anti-tumor Drug are: Roche, Takeda, Bristol-Myers Squibb, Novartis, Pfizer, Celgene, AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Biogen Idec, Otsuka, Astellas, Eisai, Bayer, Merck & Co, Teva, Sanofi, etc. Among other players domestic and global, Anti-tumor Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Table of Contents
1 Anti-tumor Drug Market Overview
1.1 Product Overview and Scope of Anti-tumor Drug
1.2 Classification of Anti-tumor Drug by Type
1.2.1 Global Anti-tumor Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Anti-tumor Drug Revenue Market Share by Type in 2019
1.2.3 Cytotoxic Drugs
1.2.4 Non-cytotoxic Drugs
1.3 Global Anti-tumor Drug Market by Application
1.3.1 Overview: Global Anti-tumor Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Alkylating Agents
1.3.3 Anti-metabolism Drugs
1.3.4 Platinum Antineoplastic Agents
1.3.5 Anthracycline antitumor drugs
1.3.6 Microtubule Stabilizer
1.3.7 Endocrine Therapy Drugs
1.3.8 Immunotherapy Drugs
1.3.9 Gene Therapy Drugs
1.3.10 Targeted Antineoplastic Drugs
1.4 Global Anti-tumor Drug Market by Regions
1.4.1 Global Anti-tumor Drug Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Anti-tumor Drug (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anti-tumor Drug Status and Prospect (2015-2025)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Takeda SWOT Analysis
2.2.4 Takeda Product and Services
2.2.5 Takeda Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb SWOT Analysis
2.3.4 Bristol-Myers Squibb Product and Services
2.3.5 Bristol-Myers Squibb Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pfizer SWOT Analysis
2.5.4 Pfizer Product and Services
2.5.5 Pfizer Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.6 Celgene
2.6.1 Celgene Details
2.6.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Celgene SWOT Analysis
2.6.4 Celgene Product and Services
2.6.5 Celgene Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 AstraZeneca SWOT Analysis
2.7.4 AstraZeneca Product and Services
2.7.5 AstraZeneca Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Johnson & Johnson SWOT Analysis
2.8.4 Johnson & Johnson Product and Services
2.8.5 Johnson & Johnson Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Amgen SWOT Analysis
2.9.4 Amgen Product and Services
2.9.5 Amgen Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Eli Lilly SWOT Analysis
2.10.4 Eli Lilly Product and Services
2.10.5 Eli Lilly Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.11 Biogen Idec
2.11.1 Biogen Idec Details
2.11.2 Biogen Idec Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Biogen Idec SWOT Analysis
2.11.4 Biogen Idec Product and Services
2.11.5 Biogen Idec Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.12 Otsuka
2.12.1 Otsuka Details
2.12.2 Otsuka Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Otsuka SWOT Analysis
2.12.4 Otsuka Product and Services
2.12.5 Otsuka Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.13 Astellas
2.13.1 Astellas Details
2.13.2 Astellas Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Astellas SWOT Analysis
2.13.4 Astellas Product and Services
2.13.5 Astellas Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.14 Eisai
2.14.1 Eisai Details
2.14.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Eisai SWOT Analysis
2.14.4 Eisai Product and Services
2.14.5 Eisai Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.15 Bayer
2.15.1 Bayer Details
2.15.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Bayer SWOT Analysis
2.15.4 Bayer Product and Services
2.15.5 Bayer Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.16 Merck & Co
2.16.1 Merck & Co Details
2.16.2 Merck & Co Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Merck & Co SWOT Analysis
2.16.4 Merck & Co Product and Services
2.16.5 Merck & Co Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.17 Teva
2.17.1 Teva Details
2.17.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Teva SWOT Analysis
2.17.4 Teva Product and Services
2.17.5 Teva Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.18 Sanofi
2.18.1 Sanofi Details
2.18.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Sanofi SWOT Analysis
2.18.4 Sanofi Product and Services
2.18.3 Sanofi Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Anti-tumor Drug Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Anti-tumor Drug Players Market Share
3.2.2 Top 10 Anti-tumor Drug Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Anti-tumor Drug Revenue and Market Share by Regions
4.2 North America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.3 Europe Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.5 South America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
5 North America Anti-tumor Drug Revenue by Countries
5.1 North America Anti-tumor Drug Revenue by Countries (2015-2020)
5.2 USA Anti-tumor Drug Revenue and Growth Rate (2015-2020)
5.3 Canada Anti-tumor Drug Revenue and Growth Rate (2015-2020)
5.4 Mexico Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6 Europe Anti-tumor Drug Revenue by Countries
6.1 Europe Anti-tumor Drug Revenue by Countries (2015-2020)
6.2 Germany Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.3 UK Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.4 France Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.5 Russia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.6 Italy Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Anti-tumor Drug Revenue by Countries
7.1 Asia-Pacific Anti-tumor Drug Revenue by Countries (2015-2020)
7.2 China Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.3 Japan Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.4 Korea Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.5 India Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
8 South America Anti-tumor Drug Revenue by Countries
8.1 South America Anti-tumor Drug Revenue by Countries (2015-2020)
8.2 Brazil Anti-tumor Drug Revenue and Growth Rate (2015-2020)
8.3 Argentina Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Anti-tumor Drug by Countries
9.1 Middle East & Africa Anti-tumor Drug Revenue by Countries (2015-2020)
9.2 Saudi Arabia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9.3 UAE Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9.4 Egypt Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9.5 South Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Anti-tumor Drug Revenue and Market Share by Type (2015-2020)
10.2 Global Anti-tumor Drug Market Forecast by Type (2019-2024)
10.3 Cytotoxic Drugs Revenue Growth Rate (2015-2025)
10.4 Non-cytotoxic Drugs Revenue Growth Rate (2015-2025)
11 Global Anti-tumor Drug Market Segment by Application
11.1 Global Anti-tumor Drug Revenue Market Share by Application (2015-2020)
11.2 Anti-tumor Drug Market Forecast by Application (2019-2024)
11.3 Alkylating Agents Revenue Growth (2015-2020)
11.4 Anti-metabolism Drugs Revenue Growth (2015-2020)
11.5 Platinum Antineoplastic Agents Revenue Growth (2015-2020)
11.6 Anthracycline antitumor drugs Revenue Growth (2015-2020)
11.7 Microtubule Stabilizer Revenue Growth (2015-2020)
11.8 Endocrine Therapy Drugs Revenue Growth (2015-2020)
11.9 Immunotherapy Drugs Revenue Growth (2015-2020)
11.10 Gene Therapy Drugs Revenue Growth (2015-2020)
11.11 Targeted Antineoplastic Drugs Revenue Growth (2015-2020)
12 Global Anti-tumor Drug Market Size Forecast (2021-2025)
12.1 Global Anti-tumor Drug Market Size Forecast (2021-2025)
12.2 Global Anti-tumor Drug Market Forecast by Regions (2021-2025)
12.3 North America Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.4 Europe Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.6 South America Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Anti-tumor Drug Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Tables and Figures
List of Tables
Table 1. Global Anti-tumor Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Anti-tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Anti-tumor Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Anti-tumor Drug Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Roche Corporate Information, Location and Competitors
Table 6. Roche Anti-tumor Drug Major Business
Table 7. Roche Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 8. Roche SWOT Analysis
Table 9. Roche Anti-tumor Drug Product and Solutions
Table 10. Roche Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Takeda Corporate Information, Location and Competitors
Table 12. Takeda Anti-tumor Drug Major Business
Table 13. Takeda Anti-tumor Drug Total Revenue (USD Million) (2018-2019)
Table 14. Takeda SWOT Analysis
Table 15. Takeda Anti-tumor Drug Product and Solutions
Table 16. Takeda Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 18. Bristol-Myers Squibb Anti-tumor Drug Major Business
Table 19. Bristol-Myers Squibb Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 20. Bristol-Myers Squibb SWOT Analysis
Table 21. Bristol-Myers Squibb Anti-tumor Drug Product and Solutions
Table 22. Bristol-Myers Squibb Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Novartis Corporate Information, Location and Competitors
Table 24. Novartis Anti-tumor Drug Major Business
Table 25. Novartis Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 26. Novartis SWOT Analysis
Table 27. Novartis Anti-tumor Drug Product and Solutions
Table 28. Novartis Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Pfizer Corporate Information, Location and Competitors
Table 30. Pfizer Anti-tumor Drug Major Business
Table 31. Pfizer Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 32. Pfizer SWOT Analysis
Table 33. Pfizer Anti-tumor Drug Product and Solutions
Table 34. Pfizer Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Celgene Corporate Information, Location and Competitors
Table 36. Celgene Anti-tumor Drug Major Business
Table 37. Celgene Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 38. Celgene SWOT Analysis
Table 39. Celgene Anti-tumor Drug Product and Solutions
Table 40. Celgene Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. AstraZeneca Corporate Information, Location and Competitors
Table 42. AstraZeneca Anti-tumor Drug Major Business
Table 43. AstraZeneca Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 44. AstraZeneca SWOT Analysis
Table 45. AstraZeneca Anti-tumor Drug Product and Solutions
Table 46. AstraZeneca Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Johnson & Johnson Corporate Information, Location and Competitors
Table 48. Johnson & Johnson Anti-tumor Drug Major Business
Table 49. Johnson & Johnson Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 50. Johnson & Johnson SWOT Analysis
Table 51. Johnson & Johnson Anti-tumor Drug Product and Solutions
Table 52. Johnson & Johnson Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Amgen Corporate Information, Location and Competitors
Table 54. Amgen Anti-tumor Drug Major Business
Table 55. Amgen Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 56. Amgen SWOT Analysis
Table 57. Amgen Anti-tumor Drug Product and Solutions
Table 58. Amgen Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Eli Lilly Corporate Information, Location and Competitors
Table 60. Eli Lilly Anti-tumor Drug Major Business
Table 61. Eli Lilly Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 62. Eli Lilly SWOT Analysis
Table 63. Eli Lilly Anti-tumor Drug Product and Solutions
Table 64. Eli Lilly Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Biogen Idec Corporate Information, Location and Competitors
Table 66. Biogen Idec Anti-tumor Drug Major Business
Table 67. Biogen Idec Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 68. Biogen Idec SWOT Analysis
Table 69. Biogen Idec Anti-tumor Drug Product and Solutions
Table 70. Biogen Idec Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Otsuka Corporate Information, Location and Competitors
Table 72. Otsuka Anti-tumor Drug Major Business
Table 73. Otsuka Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 74. Otsuka SWOT Analysis
Table 75. Otsuka Anti-tumor Drug Product and Solutions
Table 76. Otsuka Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Astellas Corporate Information, Location and Competitors
Table 78. Astellas Anti-tumor Drug Major Business
Table 79. Astellas Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 80. Astellas SWOT Analysis
Table 81. Astellas Anti-tumor Drug Product and Solutions
Table 82. Astellas Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Eisai Corporate Information, Location and Competitors
Table 84. Eisai Anti-tumor Drug Major Business
Table 85. Eisai Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 86. Eisai SWOT Analysis
Table 87. Eisai Anti-tumor Drug Product and Solutions
Table 88. Eisai Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Bayer Corporate Information, Location and Competitors
Table 90. Bayer Anti-tumor Drug Major Business
Table 91. Bayer Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 92. Bayer SWOT Analysis
Table 93. Bayer Anti-tumor Drug Product and Solutions
Table 94. Bayer Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Merck & Co Corporate Information, Location and Competitors
Table 96. Merck & Co Anti-tumor Drug Major Business
Table 97. Merck & Co Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 98. Merck & Co SWOT Analysis
Table 99. Merck & Co Anti-tumor Drug Product and Solutions
Table 100. Merck & Co Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Teva Corporate Information, Location and Competitors
Table 102. Teva Anti-tumor Drug Major Business
Table 103. Teva Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 104. Teva SWOT Analysis
Table 105. Teva Anti-tumor Drug Product and Solutions
Table 106. Teva Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Sanofi Anti-tumor Drug Type and Application
Table 108. Sanofi Anti-tumor Drug Major Business
Table 109. Sanofi Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 110. Sanofi SWOT Analysis
Table 111. Sanofi Anti-tumor Drug Product and Solutions
Table 112. Sanofi Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Global Anti-tumor Drug Revenue (Million USD) by Players (2015-2020)
Table 114. Global Anti-tumor Drug Revenue Share by Players (2015-2020)
Table 115. Global Anti-tumor Drug Revenue (Million USD) by Regions (2015-2020)
Table 116. Global Anti-tumor Drug Revenue Market Share by Regions (2015-2020)
Table 117. North America Anti-tumor Drug Revenue by Countries (2015-2020)
Table 118. North America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Table 119. Europe Anti-tumor Drug Revenue (Million USD) by Countries (2015-2020)
Table 120. Asia-Pacific Anti-tumor Drug Revenue (Million USD) by Countries (2015-2020)
Table 121. South America Anti-tumor Drug Revenue by Countries (2015-2020)
Table 122. South America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Table 123. Middle East and Africa Anti-tumor Drug Revenue (Million USD) by Countries (2015-2020)
Table 124. Middle East and Africa Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Table 125. Global Anti-tumor Drug Revenue (Million USD) by Type (2015-2020)
Table 126. Global Anti-tumor Drug Revenue Share by Type (2015-2020)
Table 127. Global Anti-tumor Drug Revenue Forecast by Type (2021-2025)
Table 128. Global Anti-tumor Drug Revenue by Application (2015-2020)
Table 129. Global Anti-tumor Drug Revenue Share by Application (2015-2020)
Table 130. Global Anti-tumor Drug Revenue Forecast by Application (2021-2025)
Table 131. Global Anti-tumor Drug Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Anti-tumor Drug Picture
Figure 2. Global Anti-tumor Drug Revenue Market Share by Type in 2019
Figure 3. Cytotoxic Drugs Picture
Figure 4. Non-cytotoxic Drugs Picture
Figure 5. Anti-tumor Drug Revenue Market Share by Application in 2019
Figure 6. Alkylating Agents Picture
Figure 7. Anti-metabolism Drugs Picture
Figure 8. Platinum Antineoplastic Agents Picture
Figure 9. Anthracycline antitumor drugs Picture
Figure 10. Microtubule Stabilizer Picture
Figure 11. Endocrine Therapy Drugs Picture
Figure 12. Immunotherapy Drugs Picture
Figure 13. Gene Therapy Drugs Picture
Figure 14. Targeted Antineoplastic Drugs Picture
Figure 15. Global Anti-tumor Drug Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Anti-tumor Drug Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Anti-tumor Drug Revenue Market Share in 2019
Figure 24. Global Top 10 Players Anti-tumor Drug Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Anti-tumor Drug Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Anti-tumor Drug Revenue Market Share by Regions (2015-2020)
Figure 28. Global Anti-tumor Drug Revenue Market Share by Regions in 2018
Figure 29. North America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 30. Europe Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 32. South America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 34. North America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 35. North America Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 36. USA Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 37. Canada Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 39. Europe Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 41. Germany Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 42. UK Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 43. France Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 44. Russia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 45. Italy Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 48. China Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 49. Japan Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 50. Korea Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 51. India Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 53. South America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 54. South America Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 55. Brazil Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 60. UAE Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 63. Global Anti-tumor Drug Revenue Share by Type (2015-2020)
Figure 64. Global Anti-tumor Drug Revenue Share by Type in 2019
Figure 65. Global Anti-tumor Drug Market Share Forecast by Type (2021-2025)
Figure 66. Global Cytotoxic Drugs Revenue Growth Rate (2015-2020)
Figure 67. Global Non-cytotoxic Drugs Revenue Growth Rate (2015-2020)
Figure 68. Global Anti-tumor Drug Revenue Share by Application (2015-2020)
Figure 69. Global Anti-tumor Drug Revenue Share by Application in 2019
Figure 70. Global Anti-tumor Drug Market Share Forecast by Application (2021-2025)
Figure 71. Global Alkylating Agents Revenue Growth Rate (2015-2020)
Figure 72. Global Anti-metabolism Drugs Revenue Growth Rate (2015-2020)
Figure 73. Global Platinum Antineoplastic Agents Revenue Growth Rate (2015-2020)
Figure 74. Global Anthracycline antitumor drugs Revenue Growth Rate (2015-2020)
Figure 75. Global Microtubule Stabilizer Revenue Growth Rate (2015-2020)
Figure 76. Global Endocrine Therapy Drugs Revenue Growth Rate (2015-2020)
Figure 77. Global Immunotherapy Drugs Revenue Growth Rate (2015-2020)
Figure 78. Global Gene Therapy Drugs Revenue Growth Rate (2015-2020)
Figure 79. Global Targeted Antineoplastic Drugs Revenue Growth Rate (2015-2020)
Figure 80. Global Anti-tumor Drug Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Anti-tumor Drug Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Anti-tumor Drug Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 84. Europe Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 86. South America Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets